ADMA Biologics Analyst Price Targets

Wall Street analyst price targets and consensus rating for ADMA Biologics (ADMA).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

1S.Buy

3Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$23Upside to Avg. PT+129.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$20→$17
May 7, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Buy	$21→$18
May 7, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$24→$20
Apr 21, 2026	Canaccord Genuity	Gary Nachman	Initiate	Buy	$21
Apr 13, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$30→$24
Mar 26, 2026	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	—
May 8, 2025	Raymond James	Elliot Wilbur	PT Raise	Strong Buy	$25→$32
Mar 4, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$25
Nov 8, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$18→$26
Nov 8, 2024	Raymond James	Elliot Wilbur	PT Raise	Strong Buy	$18→$25
Oct 14, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Sep 20, 2024	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$20
Aug 12, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$10→$18
Aug 9, 2024	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$15→$20
Jul 9, 2024	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$10→$15
Jun 20, 2024	Mizuho	Anthony Petrone	PT Raise	Buy	$12→$14
May 10, 2024	Raymond James	Elliot Wilbur	PT Raise	Strong Buy	$8→$10
May 10, 2024	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$8→$10
May 10, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$8→$10
May 10, 2024	Mizuho	Anthony Petrone	PT Raise	Buy	$10→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.

Benzinga Newsdesk

This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think about QCOM stock.

Avi Kapoor

PRO
Cantor Fitzgerald Downgrades ADMA Biologics to Neutral

Cantor Fitzgerald analyst Kristen Kluska downgrades ADMA Biologics (NASDAQ:ADMA) from Overweight to Neutral.

Benzinga Newsdesk

ADMA Biologics Inc

ADMA Biologics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

PRO
Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

PRO
Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

PRO
Cantor Fitzgerald Downgrades ADMA Biologics to Neutral

People Also Watch

People Also Watch

ADMA Biologics Inc

ADMA Biologics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

PROCanaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

PROMizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

PROCanaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

PROCantor Fitzgerald Downgrades ADMA Biologics to Neutral

People Also Watch

People Also Watch

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

PRO
Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

PRO
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

PRO
Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

PRO
Cantor Fitzgerald Downgrades ADMA Biologics to Neutral